Helen L. Lowe

13.5k total citations
16 papers, 380 citations indexed

About

Helen L. Lowe is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Helen L. Lowe has authored 16 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Epidemiology and 4 papers in Neurology. Recurrent topics in Helen L. Lowe's work include Neuroendocrine Tumor Research Advances (5 papers), Lung Cancer Research Studies (5 papers) and Neuroblastoma Research and Treatments (4 papers). Helen L. Lowe is often cited by papers focused on Neuroendocrine Tumor Research Advances (5 papers), Lung Cancer Research Studies (5 papers) and Neuroblastoma Research and Treatments (4 papers). Helen L. Lowe collaborates with scholars based in United Kingdom, United States and India. Helen L. Lowe's co-authors include John A. Hartley, Tim Meyer, Martyn Caplin, Mohid S. Khan, RB Pedley, Leah Ensell, Robert M. Goldstein, Theodora Tsigani, Amy A. Kirkwood and Christos Toumpanakis and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Scientific Reports.

In The Last Decade

Helen L. Lowe

16 papers receiving 379 citations

Peers

Countries citing papers authored by Helen L. Lowe

Since Specialization

Citations

This map shows the geographic impact of Helen L. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen L. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen L. Lowe more than expected).

Fields of papers citing papers by Helen L. Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen L. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen L. Lowe. The network helps show where Helen L. Lowe may publish in the future.

Co-authorship network of co-authors of Helen L. Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Helen L. Lowe. A scholar is included among the top collaborators of Helen L. Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen L. Lowe. Helen L. Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK 2023 ·BMJ Open ·Kenrick Ng, (unknown), Joseph J. Sacco, Anthony Kong, Graham Wheeler, Sharon Forsyth, (unknown), Joseph Ward, Leah Ensell, Helen L. Lowe, Victoria J. Spanswick, John A. Hartley, (unknown), (unknown), Martin Förster	2
2	PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer 2022 ·British Journal of Cancer ·David Propper, (unknown), Mark Saunders, Debashis Sarker, John A. Hartley, Victoria J. Spanswick, Helen L. Lowe, (unknown), Tony Ng, Paul R. Barber, Gregory Weitsman, Sarah Pearce, (unknown), Andre Lopes, Sharon Forsyth, Daniel Hochhauser	9
3	Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms 2021 ·Endocrine Related Cancer ·(unknown), Christopher D. Steele, (unknown), Francesca Rizzo, Leah Ensell, Helen L. Lowe, Pawan Dhami, (unknown), Tu Vinh Luong, Lucía Conde, Javier Herrero, Martyn Caplin, Christos Toumpanakis, Christina Thirlwell, John A. Hartley, Nischalan Pillay, Tim Meyer	10
4	922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas 2020 ·Annals of Oncology ·Martin Förster, Robert Metcalf, Joseph J. Sacco, Anthony Kong, Graham Wheeler, Sharon Forsyth, (unknown), (unknown), (unknown), Helen L. Lowe, Victoria J. Spanswick, Leah Ensell, (unknown), (unknown)	5
5	979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck 2020 ·Annals of Oncology ·Sharon Forsyth, (unknown), Bernadette Foran, Paul Gougis, Graham Wheeler, (unknown), (unknown), (unknown), (unknown), Victoria J. Spanswick, Helen L. Lowe, (unknown), Martin Förster	2
6	Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors 2020 ·The Journal of Clinical Endocrinology & Metabolism ·Dalvinder Mandair, Mohid S. Khan, Andre Lopes, (unknown), Leah Ensell, Helen L. Lowe, John A. Hartley, Christos Toumpanakis, Martyn Caplin, Tim Meyer	15
7	Development of a novel patient focussed symptom severity index for use in assessing and treating inflammatory conditions of the lactating breast: a Delphi study 2020 ·International Journal of Evidence-Based Healthcare ·(unknown), Helen L. Lowe, (unknown)	4
8	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 2019 ·British Journal of Cancer ·Francesca Rizzo, (unknown), (unknown), Teresa Marafioti, Mohid S. Khan, Dalvinder Mandair, Mauro Cives, Leah Ensell, Helen L. Lowe, Ayse U. Akarca, Tu Vinh Luong, Martyn Caplin, Christos Toumpanakis, Daniel Krell, Christina Thirlwell, Franco Silvestris, John A. Hartley, Tim Meyer	29
9	EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer. 2019 ·Journal of Clinical Oncology ·Martin Förster, Joseph J. Sacco, (unknown), Graham Wheeler, Sharon Forsyth, (unknown), (unknown), Helen L. Lowe, Victoria J. Spanswick, Leah Ensell, John A. Hartley, (unknown)	4
10	Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours 2016 ·British Journal of Cancer ·(unknown), (unknown), Leah Ensell, Helen L. Lowe, Tu Vinh Luong, Martyn Caplin, Christos Toumpanakis, Christina Thirlwell, John A. Hartley, Tim Meyer	32
11	Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer 2016 ·Oncology ·Charlotte Lemech, Leah Ensell, Jennifer C. Paterson, Gemma Eminowicz, Helen L. Lowe, Rupali Arora, Hendrik‐Tobias Arkenau, Martin Widschwendter, Nicola MacDonald, Adeola Olaitan, Tim Mould, Tim Meyer, John A. Hartley, Anita Mitra, Jonathan A. Ledermann, Mary McCormack, Rebecca Kristeleit	18
12	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms 2015 ·Clinical Cancer Research ·Mohid S. Khan, Amy A. Kirkwood, Theodora Tsigani, Helen L. Lowe, Robert M. Goldstein, John A. Hartley, Martyn Caplin, Tim Meyer	66
13	A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancer 2015 ·Scientific Reports ·Stephan A. Ohnmacht, Chiara Marchetti, Mekala Gunaratnam, (unknown), Shozeb Haider, (unknown), Helen L. Lowe, (unknown), Seckou Diocou, Mathew Robson, Jiřı́ Šponer, Barira Islam, RB Pedley, John A. Hartley, Stephen Neidle	93
14	Evidence for different mechanisms of ‘unhooking’ for melphalan and cisplatin-induced DNA interstrand cross-links in vitroand in clinical acquired resistant tumour samples 2012 ·BMC Cancer ·Victoria J. Spanswick, Helen L. Lowe, Claire Newton, John P. Bingham, (unknown), Konstantinos Kiakos, Charles Craddock, Jonathan A. Ledermann, Daniel Hochhauser, John A. Hartley	24
15	Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells 2007 ·British Journal of Cancer ·Chris Pepper, Helen L. Lowe, Chris Fegan, Christophe Thurieau, David E. Thurston, J.A. Hartley, Patrick Delavault	17
16	Sustained Tumor Regression of Human Colorectal Cancer Xenografts Using a Multifunctional Mannosylated Fusion Protein in Antibody-Directed Enzyme Prodrug Therapy 2005 ·Clinical Cancer Research ·Surinder K. Sharma, RB Pedley, (unknown), Geoffrey M. Boxer, Ethaar El‐Emir, Uzma Qureshi, Berend Tolner, Helen L. Lowe, (unknown), Nigel P. Minton, Richard H. J. Beǵent, Kerry Chester	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact